Prosecution Insights
Last updated: November 20, 2026
Application No. 18/689,161

METHODS OF TREATING NEURODEGENERATIVE CONDITIONS AND COMPOSITIONS THEREFOR

Non-Final OA §102§112§DOUBLEPATENT
Filed
Mar 05, 2024
Priority
Sep 07, 2021 — provisional 63/241,140 +1 more
Examiner
VAN BUREN, LAUREN K
Art Unit
1638
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Yale University
OA Round
1 (Non-Final)
40%
Grant Probability
Moderate
1-2
OA Rounds
1y 6m
Est. Remaining
98%
With Interview

Examiner Intelligence

Grants 40% of resolved cases
40%
Career Allowance Rate
170 granted / 425 resolved
-20.0% vs TC avg
Strong +58% interview lift
Without
With
+58.4%
Interview Lift
resolved cases with interview
Typical timeline
4y 2m
Avg Prosecution
46 currently pending
Career history
481
Total Applications
across all art units

Statute-Specific Performance

§101
2.5%
-37.5% vs TC avg
§103
49.5%
+9.5% vs TC avg
§102
10.2%
-29.8% vs TC avg
§112
25.1%
-14.9% vs TC avg
Black line = Tech Center average estimate • Based on career data from 425 resolved cases

Office Action

§102 §112 §DOUBLEPATENT
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Restriction/Election Applicant's election with traverse of Group I (Claims 1-7), Alzheimer’s disease (Species II), and nucleic acid (Species III) in the reply filed on September 14, 2026 is acknowledged. The traversal is on the ground that there is no serious search burden for examining all 20 related claims. The examiner did not find this argument to be persuasive since the application is a 371 case; therefore, restriction is based on unity of invention not search burden. In this case, the technical feature cited in the restriction was not a special technical feature and does not make a contribution over the prior art in view of Tjernberg (WO 2010/140694) as addressed in the 102 rejection below. The examiner has decided to rejoin a prevention method (Species I) into the claims so that enablement issues relating to the term “prevention” can be addressed, thus facilitating compact prosecution. The requirement is still deemed proper and is therefore made FINAL. Claims 8-20, non-elected species (Species II), and non-elected species (Species III) are withdrawn from further consideration pursuant to 37 CFR 1.142(b), as being drawn to a nonelected Groups II-III and non-elected species, there being no allowable generic or linking claim. Applicant timely traversed the restriction (election) requirement in the reply filed on September 14, 2026. Claims Objection Claims 1 and 7 are objected to because of the following informalities: PLD3 is an abbreviation and the term “phospholipase D3” needs to be added to the claims. Appropriate correction is required. Claim Rejections - 35 USC § 112 The following is a quotation of the first paragraph of 35 U.S.C. 112(a): (a) IN GENERAL.—The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor or joint inventor of carrying out the invention. The following is a quotation of the first paragraph of pre-AIA 35 U.S.C. 112: The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor of carrying out his invention. Claims 1-7 are rejected under 35 U.S.C. 112(a) or 35 U.S.C. 112 (pre-AIA ), first paragraph, because the specification, while being enabling for a method of reversing the formation or enlargement of an axonal spheroid, the method comprising: contacting a neuron affected by the formation or enlargement of the axonal spheroid with a compound that downregulates an expression level or an activity of PLD3, does not reasonably provide enablement for a method of reversing or preventing the formation or enlargement of an axonal spheroid, the method comprising: contacting a neuron affected by the formation or enlargement of the axonal spheroid with a compound that downregulates an expression level or an activity of PLD3. The specification does not enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to use the invention commensurate in scope with these claims. The test of enablement is whether one skilled in the art could make and use the claimed invention from the disclosures in the application coupled with information known in the art without undue experimentation (United States v. Telectronics, Inc. 8 USPQD2d 1217 (Fed. Cir. 1988). Whether undue experimentation is required is a conclusion reached by weighing several factors. These factors were outlined in Ex parte Forman, 230 USPQ 546 (Bd. Pat. App. & Inter. 1986) and again in In re Wands, 8 USPQQ2d 1400 (Fed. Cir. 1988). While determining whether a specification is enabling, one considers whether the claimed invention provides sufficient guidance to make and use the claimed invention, if not, whether an artisan would require undue experimentation to make and use the claimed invention and whether working examples have been provided. When determining whether a specification meets the enablement requirements, some of the factors that need to be analyzed are: the breadth of the claims, the nature of the invention, the state of the prior art, the level of one of ordinary skill, the level of predictability in the art, the amount of direction provided by the inventor, the existence of working examples, and whether the quantity of any necessary experiment to make and use the invention based on the content of the disclosure is undue. Nature of the Invention: The invention encompasses a method of reversing or preventing a formation and/or enlargement of an axonal spheroid by contacting a neuron affected by formation or enlargement of the axonal spheroid with a compound that downregulates an expression level and/or activity of PLD3. Breadth of the Claims: The claims are so broad that they encompass methods of prevention. Prevention means that a condition is prevented from ever occurring no matter what the circumstances are. The claims are so broad that they encompass any method of administration to any part of the body. Teachings from the Prior Art: Tjernberg (WO 2010140694) discloses that antisense nucleic acid treatments can be administered to a human or non-human mammal (e.g. rat, rabbit, sheep, pig, bovine, cat, dog, monkey, etc). orally or parenterally (e.g. intravascular administration, subcutaneous administration, etc.) as a liquid formulation or as a suitable dosage form of pharmaceutical composition (Paragraph 45 of Tjernberg). The prior art reference focuses on an oral administration method or a method of administration that involves administration into the body. There is no teaching that antisense nucleic acid treatments can be successfully administered in a cream applied to body region such as the feet to treat formation and/or enlargement of axonal spheroids. There is no teaching that antisense therapy always can prevent neurodegenerative conditions and/or formation/enlargement of axonal spheroids. Applicants Specification/Guidance/Working Examples: Paragraph 76 of applicants’ specification states that administration methods can include: subcutaneous, intravenous, oral, aerosol, inhalation, rectal, vaginal, transdermal, intranasal, buccal, sublingual, parenteral, intrathecal, intragastrical, ophthalmic, pulmonary, and topical administration (Paragraph 76 of the specification).” However, this is a general statement for all the agents that can be administered and not just the nucleic acid agents. The reference states that RNA interference/antisense molecules can be used to downregulate the expression level of PLD3 (Paragraph 105-116). Paragraph 119-131 describe that CRISPR can also be used to down regulate activity or expression PLD3 level. The specification does not adequately show that the nucleic acid therapeutic agents taught in the specification used to downregulate PLD3 can always prevent formation/enlargement of an axonal spheroid. The specification does not show that a composition containing a nucleic acid that downregulates the expression level and/or activity of PLD3 can be successfully administered in a topical cream and placed on any area of the body. Conclusion: Neither the specification or the prior art provide evidence that formation and/or enlargement of axonal spheroid can always be prevented by contacting a neuron with a compound that downregulates an expression level and/or activity level of PLD3. Furthermore, the specification and prior art only support methods of administration within the body: subcutaneous, intravenous, oral, aerosol, inhalation, rectal, vaginal, transdermal, intranasal, buccal, sublingual, parenteral, intrathecal, intragastrical, ophthalmic, pulmonary. There is no enabled support for topical administration using nucleic acid that downregulates the expression level and/or activity of PLD3 by RNA interference and/or an expression vector expressing the nucleic acid that downregulates the expression level and/or activity of PLD3 by RNA interference. Claim Rejections - 35 USC § 102 The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention. Claims 1-7 are rejected under 35 U.S.C. 102(a)(1) as being anticipated by Tjernberg (WO 2010140694) Tjernberg discloses contacting a neuron affected by the formation or enlargement of the axon spheroid with a compound that downregulates an expression level and/or activity of PLD3 (Abstract, Paragraphs 81-21 and 40 of Tjernberg) as in instant Claim 1. Tjernberg discloses wherein the axonal spheroid blocks or delays a propagation of an action potential (AP) along an axon of the neuron(Abstract, Paragraphs 81-21 and 40 of Tjernberg) as in instant Claim 2. Tjjernberg discloses wherein the formation and/or enlargement of axonal spheroids is associated with a neurodegenerative conditions (Alzeheimer’s disease) (Abstract of Tjernberg) as in instant Claims 4-5. The composition treats Alzheimer’s disease; Alzheimer’s disease is characterized by amyloid plaques and enlarged axonal spheroids (Abstract) as in instant Claim 6. Tjernberg discloses a nucleic acid that downregulates the expression level or activity of PLD3 by RNA interference (Paragraphs 18-21 of Tjernberg) as in instant Claim 7. The reference anticipates the instant set of claims. Double Patenting The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the “right to exclude” granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., In re Berg, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); In re Goodman, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); In re Longi, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); In re Van Ornum, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); In re Vogel, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); In re Thorington, 418 F.2d 528, 163 USPQ 644 (CCPA 1969). A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on nonstatutory double patenting provided the reference application or patent either is shown to be commonly owned with the examined application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement. See MPEP § 717.02 for applications subject to examination under the first inventor to file provisions of the AIA as explained in MPEP § 2159. See MPEP § 2146 et seq. for applications not subject to examination under the first inventor to file provisions of the AIA . A terminal disclaimer must be signed in compliance with 37 CFR 1.321(b). The filing of a terminal disclaimer by itself is not a complete reply to a nonstatutory double patenting (NSDP) rejection. A complete reply requires that the terminal disclaimer be accompanied by a reply requesting reconsideration of the prior Office action. Even where the NSDP rejection is provisional the reply must be complete. See MPEP § 804, subsection I.B.1. For a reply to a non-final Office action, see 37 CFR 1.111(a). For a reply to final Office action, see 37 CFR 1.113(c). A request for reconsideration while not provided for in 37 CFR 1.113(c) may be filed after final for consideration. See MPEP §§ 706.07(e) and 714.13. The USPTO Internet website contains terminal disclaimer forms which may be used. Please visit www.uspto.gov/patent/patents-forms. The actual filing date of the application in which the form is filed determines what form (e.g., PTO/SB/25, PTO/SB/26, PTO/AIA /25, or PTO/AIA /26) should be used. A web-based eTerminal Disclaimer may be filled out completely online using web-screens. An eTerminal Disclaimer that meets all requirements is auto-processed and approved immediately upon submission. For more information about eTerminal Disclaimers, refer to www.uspto.gov/patents/apply/applying-online/eterminal-disclaimer. Claims 1-7 are provisionally rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1,4-7,9-18 of copending Application No. 19/133,296 (reference application). Although the claims at issue are not identical, they are not patentably distinct from each other because both instant claim 1 and claims 1, 4, and 9,15 of Application 19/133,296 disclose administration of an agent that would downregulate the expression level and/or activity level of PLD3, capable of reversing or preventing formation and/or enlargement of an axonal spheroid. Instant claim 2 corresponds to claim 10 of Application 19/133,296. Instant claim 3 corresponds to claim 11 of Application 19/133,296. Instant claim 4 corresponds to claims 12 and 16 of Application 19/133,296. Instant claim 5 corresponds to claim 13 of Application 19/133,296. Instant claim 6 corresponds to claim 13 of Application 19/133,296. Instant claim 7 corresponds to claims 5-7,14,17-18 of Application 19/133,296. This is a provisional nonstatutory double patenting rejection because the patentably indistinct claims have not in fact been patented. Conclusion All claims stand rejected. Any inquiry concerning this communication or earlier communications from the examiner should be directed to LAUREN K VAN BUREN whose telephone number is (571)270-1025. The examiner can normally be reached M-F:9:30am-5:40pm; 9:00-10:00pm. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Tracy Vivlemore can be reached at 571-272-2914. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. LAUREN K. VAN BUREN Examiner Art Unit 1638 /Tracy Vivlemore/Supervisory Primary Examiner, Art Unit 1638
Read full office action

Prosecution Timeline

Mar 05, 2024
Application Filed
Nov 05, 2026
Non-Final Rejection mailed — §102, §112, §DOUBLEPATENT (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12788784
Products Derived from Amniotic Fluid and Methods of Use
3y 11m to grant Granted Nov 10, 2026
Patent 12775005
KETONE BODY SENSING DEVICE AND METHOD
6y 1m to grant Granted Oct 27, 2026
Patent 12773437
ONCOLYTIC VIRUSES AND METHODS FOR USING ONCOLYTIC VIRUSES
5y 2m to grant Granted Oct 27, 2026
Patent 12760267
ORGANOID ARRAYS
7y 7m to grant Granted Oct 13, 2026
Patent 12741026
Microparticle-Assisted Treg Therapy for Treatment of Tissue Injury and Fibrosis
3y 11m to grant Granted Sep 22, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
40%
Grant Probability
98%
With Interview (+58.4%)
4y 2m (~1y 6m remaining)
Median Time to Grant
Low
PTA Risk
Based on 425 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month